Welcome
Support Centre
11 February 2012 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
The effect of locally applied autologous platelet-rich fibrin sealant on woundhealing
ISRCTN ISRCTN34481461
ClinicalTrials.gov identifier
Public title The effect of locally applied autologous platelet-rich fibrin sealant on woundhealing
Scientific title
Acronym The IMPRA-project
Serial number at source KF (01) 264835
Study hypothesis Platelet-rich fibrin enhances and accelerates wound healing
Lay summary
Ethics approval Not provided at time of registration
Study design Randomised controlled trial
Countries of recruitment Denmark
Disease/condition/study domain Cholelithiasis
Participants - inclusion criteria Consecutive patients undergoing elective laparoscopic cholecystectomy, over 18 years old who have given written and verbal informed consent.
Participants - exclusion criteria 1. Not Danish-speaking
2. Demential
3. Pregnant or lactating women
4. Fertile women not using contraception
5. Patients on aspirin (acetylsalicylic acid [ASA]) or anticoagulants less than 7 days before surgery
6. Patients suffering from anaemia or coagulation disorders
7. Patients suffering from incompensated heart or lung disease
Anticipated start date 01/08/2005
Anticipated end date 01/09/2006
Status of trial Completed
Patient information material
Target number of participants 50
Interventions Surgical wounds treated with trial product (platelet-rich fibrin) or control.
Primary outcome measure(s) Collagen synthesis
Secondary outcome measure(s) 1. Woundstrength
2. Production of type I and III collagen mRNA
3. Histology
4. Growthfactors
5. Unwanted effects
Sources of funding Vivolution A/S (Denmark)
Trial website
Publications 2010 results in http://www.ncbi.nlm.nih.gov/pubmed/20395860
Contact name Dr  Lars Nannestad  Jørgensen
  Address Afd. K
Bispebjerg Hospital
Bispebjerg Bakke 23
  City/town Copenhagen
  Zip/Postcode 2400 NV
  Country Denmark
  Tel +45 (0)3531 2856
  Fax +45 (0)3531 3911
  Email larsnjorgensen@hotmail.com
Sponsor Vivolution A/S (Denmark)
  Address Blokken 45
DK-3460 Birkerod
  City/town Birkerod
  Zip/Postcode 3460
  Country Denmark
  Tel +45 (0)4581 1962
  Fax +45 (0)4582 4800
  Email info@vivolution.com
  Sponsor website: http://www.vivolution.com
Date applied 29/07/2005
Last edited 17/05/2010
Date ISRCTN assigned 06/10/2005
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 ISRCTN unless otherwise stated.


BioMed Central